A phase II trial (NCT03925974) showed that patients with HER2-expressing advanced GC or GEJA receiving KN026 had an objective response rate (ORR) of 56% and a durable remission duration of 9.7 months [39]. This evidence concerns the gene ERBB2 and gastric cancer.